Despite the importance of activated AKT in pan-cancers and tremendous efforts to develop AKT-targeted therapies, results from clinical trials of various AKT inhibitors remain suboptimal, even in combination with inhibitors targeting its downstream protein effectors, suggesting that AKT-driven tumor metastasis needs to be further investigated and understood. The gene discussed is AKT1; the disease is neoplasm.